Development of the DermaPort
Abram Janis, DermaPort

Wednesday, May 27 2009 7 PM
CLU - Ahmanson Science Building

Providing reliable, infection-resistant access to a chronic kidney disease patient's vasculature has been a challenge throughout the history of dialysis.  In 2005, a group of visionary leaders established Dermaport to help patients who require physically invasive therapies such as CKD to have a better quality of life.  With the support of entrepreneur and philanthropist Alfred E. Mann, Dermaport was formed to develop devices that retain fixation and resist infection at the percutaneous interface of the skin.

This presentation will describe the development of the PVAS(TM) Ported Vascular Access System, a specially-designed central venous catheter coupled to a port for long-term hemodialysis.

Abram Janis, DermaPort

Abram Janis is the Director of Research at DermaPort.  In that role, he plans and manages clinical trials and submissions to the FDA for DermaPort's medical devices.  He holds a Master's in Biology from Portland State University, and has done post-graduate study at Purdue University. 

Abe is the Buenaventura EMBS Chapter's Industrial Relations officer.